Compugen Announces Data To Be Presenteed At SCO Showing COM701 Demonstrates Preliminary Durable Anti-Tumor Activity In Triple Immunotherapy Combination In Patients With Recurrent Metastatic MSS Endometrial Cancer
Portfolio Pulse from Benzinga Newsdesk
Compugen announced that data on COM701, a triple immunotherapy combination for recurrent metastatic MSS endometrial cancer, will be presented at the Society for Immunotherapy of Cancer (SITC) conference. The data shows preliminary durable anti-tumor activity.
June 05, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen's COM701 demonstrates preliminary durable anti-tumor activity in triple immunotherapy combination for recurrent metastatic MSS endometrial cancer.
The announcement of positive preliminary data on COM701's anti-tumor activity in a triple immunotherapy combination for endometrial cancer is likely to have a positive short-term impact on Compugen's stock price. The presentation at the SITC conference will increase visibility and potentially attract more investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100